Biomarker significance of plasma and tumor miR-21, miR-221, and miR-106a in osteosarcoma

Manjula Nakka1,2, Wendy Allen-Rhoades1,2,4, Yiting Li1,2, Aaron J. Kelly2,3, Jianhe Shen1,2, Aaron M. Taylor2,3, Donald A. Barkauskas5,6, Jason T. Yustein1,2,4, Irene L. Andrulis7,8, Jay S. Wunder9, Richard Gorlick6, Paul S. Meltzer10, Ching C. Lau1,2,3,4 and Tsz-Kwong Man1,2,3,4, the TARGET osteosarcoma consortium

1Texas Children’s Cancer and Hematology Centers, Texas Children’s Hospital, Houston, TX, USA
2Department of Pediatrics, and Baylor College of Medicine, Houston, TX, USA
3Program of Structural and Computational Biology and Molecular Biophysics, Baylor College of Medicine, Houston, TX, USA
4Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX, USA
5Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
6Children’s Oncology Group, Monrovia, CA, USA
7Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, ON, Canada
8Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada
9Department of Surgery, University of Toronto, Toronto, ON, Canada
10Genetics Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

*Ching Lau, Paul Meltzer, Sean David, Josh Waterfall, Sven Bilke, Malcolm Smith, Daniela Gerhard, Jaime Guidary Auvil, Tanja Davidsen, Leandro Hermida, Patee Gesuwan, Richard Gorlick, Don Barkauskas, Mark Kralio, Chand Khanna, Neyssa Marina, Lisa Teot, Julie Gastier-Foster, Nicole Ross, Yvonne Moyer, Laura Monovich, Mary McNulty, Irene Andrulis, Nalan Gokgoz, Shintaro Iwata, Miki Ohira, Silvia Caminada De Toledo, Sergio Petrilli, Jiayi Sun, Aaron Taylor, Jianhe Shen and Tsz-Kwong Man

Correspondence to: Tsz-Kwong Man, email: ctman@txch.org

Keywords: miRNA, osteosarcoma, biomarker, plasma, prognosis

Received: December 09, 2016   Accepted: May 15, 2017   Published: May 27, 2017

Copyright: Nakka et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

Osteosarcoma is the most common malignant bone tumor in children and young adults. Despite the use of surgery and multi-agent chemotherapy, osteosarcoma patients who have a poor response to chemotherapy or develop relapses have a dismal outcome. Identification of biomarkers for active disease may help to monitor tumor burden, detect early relapses, and predict prognosis in these patients. In this study, we examined whether circulating miRNAs can be used as biomarkers in osteosarcoma patients. We performed genome-wide miRNA profiling on a discovery cohort of osteosarcoma and control plasma samples. A total of 56 miRNAs were upregulated and 164 miRNAs were downregulated in osteosarcoma samples when compared to control plasma samples. miR-21, miR-221 and miR-106a were selected for further validation based on their known biological importance. We showed that all three circulating miRNAs were expressed significantly higher in osteosarcoma samples than normal samples in an independent cohort obtained from the Children’s Oncology Group. Furthermore, we demonstrated that miR-21 was expressed significantly higher in osteosarcoma tumors compared with normal bone controls. More importantly, lower expressions of miR-21 and miR-221, but not miR-106a, significantly correlated with a poor outcome. In conclusion, our results indicate that miR-21, miR-221 and miR-106a were elevated in the circulation of osteosarcoma patients, whereas tumor expressions of miR-21 and miR-221 are prognostically significant. Further investigation of these miRNAs may lead to a better prognostic method and potential miRNA therapeutics for osteosarcoma.
INTRODUCTION

Osteosarcoma (OS) is the most frequent primary malignant bone tumor in pediatric patients comprising of 55% of all bone tumors [1, 2]. Introduction of combination chemotherapy in the 1970s and surgery for localized tumor led to a significant increase in survival rates to 60–70%. However, metastasis is detected in approximately 25% of the patients and the cure rate for patients with metastatic or relapsed disease remains poor (< 20% survival) [3, 4]. Several clinical features are known to be strong prognostic predictors, such as primary metastases, tumor size, complete surgical resection and histologic response to chemotherapy [5]. Further, a retrospective study demonstrated that the time of identification of pulmonary metastases, which is the most prevalent form of metastases in OS, has a significant effect on survival rates. Identification of metastases at the time of diagnosis resulted in a 5-year survival rate of 18% compared to 0% and 6% rates for those identified at the time of preoperative and postoperative chemotherapy [6]. Biomarkers are increasingly used in cancer treatment to refine risk stratification and augment current clinical decision making tools, such as radiographic imaging. Biomarkers can improve or complement the accuracy, sensitivity and specificity of the routinely used detection and imaging methods. For instance, in a recent breast cancer study a circulating 9-miRNA signature accurately predicts recurrence in a patient designated as healthy by mammography [7]. Hence, blood based biomarkers could be useful for monitoring of disease progression and early detection of relapse. Currently no sensitive and specific non-invasive, diagnostic biomarker to distinguish OS from healthy controls exists. Discovery of non-invasive or tumor biomarkers for early detection or prognostication could improve survival of the patients with OS.

miRNAs are small noncoding regulatory RNA molecules, whose main biological function is to increase or decrease the activity of specific mRNAs and ultimately their translation into proteins [8]. Cell-free circulating miRNAs have shown promise as blood-based biomarkers due to their high stability despite endogenous RNAses and long-term storage, as well as ease of isolation and detection [9]. Additionally, they are easily detected in body fluids, consist of simple chemical compositions without complex modifications, are highly conserved between species, and are expressed in a tissue-specific manner [10]. Emerging evidence shows they are dysregulated in cancer, which could provide alternate or additional means of diagnosis, prognosis, and treatment [11]. Using a mouse xenograft model of prostate cancer, a previous study has demonstrated that miRNAs exclusively expressed by human prostate cancer cells are readily detectable in the circulation of xenograft mice, but not in the control mice [9].

Different types of circulating miRNA biomarkers have been discovered in cancers that can be used for monitoring tumor presence/burden or for predicting disease recurrence. There are increasing reports of using either a single miRNA [12] or a signature as a biomarker [13]. For example in breast cancer, circulating miR-10b and miR-373 levels are significantly higher in breast cancer patients with lymph node metastasis compared to both normal and breast cancer patients with no metastasis, indicating that they may be useful as biomarkers for metastases [14]. In gastric cancer, miR-203 levels in serum showed potential to be a predictor of metastases, recurrence and prognosis [15]. Differential expression of five plasma miRNAs (miR-16, miR-25, miR-92a, miR-451 and miR-486-5p) by microarray profiling suggested that they are potential biomarkers for an early stage of gastric cancer [16]. A profile of miR-21, miR-29a, miR-25, miR-200a and miR-486-5p has been identified as a cervical cancer biomarker and miR-29a and miR-200a are associated with the histological grade and the progression stage [17]. All these studies have demonstrated the rapidly growing field of harnessing circulating miRNAs as biomarkers for cancer detection and prognostication.

In addition to circulating miRNAs, tumor miRNAs have also been extensively exploited as cancer biomarkers [18]. For instance, miRNAs have been shown to be diagnostic and prognostic biomarkers in lung cancer [19]. Other genome-wide miRNA profiling or specific miRNA studies have identified both diagnostic and prognostic biomarkers in various cancer types [20–23]. Tumor miRNA biomarkers have also been shown to differentiate two types of skin cancer, i.e. basal cell carcinoma and Merkel cell carcinoma [24], distinguish brain-metastasizing melanoma from non-brain metastasizing tumors [25] and predict chemotherapy response in primary lung adenocarcinoma tissues [26].

In this study, our main goal is to perform an unbiased genome-wide discovery and validation of circulating miRNAs that are associated with OS patients at the time of diagnosis. Our results show that three miRNAs (miR-21, miR-221, and miR-106a) are significantly overexpressed in OS plasma compared to control samples and could be used as non-invasive biomarkers for OS. miR-21 was also significantly overexpressed in OS tumor samples, and tumor expression of miR-21 and miR-221 correlated with prognosis. Our results demonstrate that these miRNAs may be useful in disease detection and monitoring, as well as prognostication, of OS.

RESULTS

Genome-wide miRNA profiling identifies candidate circulating miRNAs in OS

To identify circulating biomarkers that were associated with OS, we analyzed the abundance levels of 752 miRNAs in a discovery set of OS plasma samples (n = 32) versus normal plasma samples from healthy
donors and children with noncancerous diseases (n = 8) using a locked nucleic acid (LNA)-based quantitative reverse transcription-polymerase chain reaction (qRT-PCR) platform. The results showed 220 plasma miRNAs differentially expressed between OS and healthy controls (56 upregulated and 164 downregulated in OS) (Figure 1A, Supplementary Table 5). Because of the large amount of differentially expressed miRNAs, we further screened for the most biologically relevant candidates using the following criteria: (1) up-regulated in OS cell lines [27]; (2) involved in tumorigenesis [28–30], and (3) present as circulating miRNAs in cancer [31, 32]. Based on these additional criteria, three miRNAs (miRNA-21, miR-221, and miRNA-106a), which were expressed significantly higher in OS relative to the normal controls, were selected for further evaluation (Figure 1B).

**Validation of the three candidate miRNAs in an independent plasma cohort**

To validate the higher levels of the three circulating miRNAs in OS patients when compared to normal subjects, LNA-based qRT-PCR was performed on an independent cohort of human plasma samples obtained from the Children’s Oncology Group (n = 29) and healthy donor controls (n = 17). The results demonstrated that all the three selected miRNAs were expressed significantly higher (p < 0.05 and fold change (FC) > 2-fold) in OS samples when compared to normal samples (Figure 2A). Furthermore, the receiver operator curve (ROC) analysis showed that all three circulating miRNAs had very good diagnostic characteristics with AUC values > 0.8, with miR-106a being the best (Figure 2B).

**Tumor expression of three miRNAs in OS**

Since the three miRNAs were elevated in the peripheral blood samples of OS patients, we tested if these circulating miRNAs were also overexpressed in OS tumor tissues. We compared the expressions of the miRNAs in 89 OS tumor tissue samples obtained from our TARGET initiative with five normal bone controls, which included two samples of fetal normal human bone (FNB), two samples of normal human bone (NB), and one sample of normal human osteoblast (NHOst). The analysis showed that only miR-21 was significantly overexpressed in the tumor tissues (p < 0.001, FC = 7.56) (Figure 3A). To confirm if miR-21 was expressed in OS tumor tissues, we examined the miR-21 expression in an OS tissue microarray (TMA) using in-situ hybridization (Figure 3B).

U6 and scrambled probes were used as a positive and a negative control, respectively. We tabulated the miR-21 expression in the TMA (Figure 3B) and found that miR-21 was expressed in approximately 70% of the OS tissues.

**Prognostic significance of the three miRNAs**

Despite only miR-21 showing overexpression in the OS tumors, we tested whether expression of each miRNA correlated with prognosis. Survival analysis showed that lower expression levels of both miR-21 (p = 0.0135, HR = 0.71) and miR-221 (p = 0.0004, HR = 0.57), but not miR-106a (p = 0.07, HR = 1.39), were significantly associated with poor overall survival in the continuous COXPH analysis. Similar results were also observed for event-free survival (Supplementary Table 1). The survival curves of the high and low expression levels of miR-21 and miR-221 using the first quartile as a cutoff displayed a significant separation (Figure 4A and 4B). Since metastasis is a known prognostic factor at diagnosis, we tested if the prognostic significance of miR-21 and miR-221 was dependent on the metastatic status at diagnosis. The result of the stratified analysis indicated that the two miRNAs remained significant for both overall and event-free survival after controlling for metastasis at diagnosis, suggesting that the miRNAs were independent prognostic factors (Figure 4C and 4D, Supplementary Table 2). When considering only patients with metastasis at diagnosis, similar results for miR-21 and miR-221 further indicated that lower expression of the two miRNAs could identify an extremely high-risk subpopulation even among the already high-risk, metastatic patients (Figure 4C and 4D). In contrast, only miR-21 was significantly associated with event-free survival in patients with localized disease at diagnosis (Figure 4D). Consistent with the stratified analysis results, neither miR-21 nor miR-221 were significantly associated with metastasis at diagnosis. However, miR-106a expression significantly correlated with metastatic status (p = 0.035, μno_met = −0.15, μno_met = −0.69, Figure 5A and Supplementary Figure 1A), even though it was not prognostically significant.

Next, we tested if the prognostic significance of miR-21 and miR-221 was independent from another known prognostic factor in OS, i.e. histologic response to adjuvant chemotherapy. However, the histologic response can only be measured after the adjuvant chemotherapy is completed. The stratified analysis showed that none of the miRNAs were significant after controlling for the histologic response, indicating that they were not prognostically independent (Supplementary Table 3). In addition, miR-21 expression, but neither miR-221 nor miR-106a, was significantly associated with histologic response (p = 0.012, μno_good = −1.90, μno_good = −0.69, Figure 5B and Supplementary Figure 1B). Together, the results suggest that the prognostic significance of miR-21 and miR-221 may be in part explained by their association...
with the histologic response, and miR-21 may be used as a predictive biomarker in OS to identify patients who are likely to respond poorly to chemotherapy at diagnosis.

Lastly, the correlation analysis showed that miR-21 and miR-221 were significantly correlated with each other (R = 0.63, p = 3.1e-11), while both were significantly negatively correlated with miR-106a (miR-21-miR106a: R = −0.24, p = 0.02; miR-221-miR-106a: R = −0.30, p = 0.005, Figure 5C–5E). The high-risk and low-risk groups defined by miR-21 and miR-221 were significantly correlated (Fisher’s exact test, p = 5.567e-5, Figure 5F). Also, only miR-221 remained significant in a multivariate analysis of all three miRNAs for overall survival (p = 0.016), and close to significant for event-free survival (p = 0.08) (Supplementary Table 4). Among the three miRNAs, the analysis suggested that miR-221 may be the most promising prognostic biomarker for further evaluation.

DISCUSSION

Development of metastases or disease relapse is a major cause of mortality in OS. Identification of non-invasive and easy-to-use biomarkers for monitoring tumor burden or early detection of relapse has the potential to augment the clinical care of patients with OS. Extracellular miRNAs can be detected in various biofluids, including whole blood, plasma and serum. Circulating
miRNAs are stable in these body fluids by binding to proteins or enclosed in vesicles, rendering them to be a good source for biomarker studies in various diseases [33, 34]. Based on published circulating miRNA studies in OS, we found that serum samples were more frequently used than plasma. Although whole blood samples have also been used in other cancers like breast cancer [35], it has not been reported in OS. Notably, comparison of miRNA expression levels between serum and plasma samples by previous studies have shown that the miRNA levels in these two types of blood samples are highly correlated [36]. However, another study has shown that specific miRNAs may not consistently be detected among serum, plasma and whole blood, such as miR-504 and miR-138. Caution should be exercised in selecting the appropriate sample type if detection of specific circulating miRNAs is required [37].

In this study, we identified and subsequently validated three miRNAs, miR-21, miR-106a and miR-221, which were elevated in the peripheral blood samples of OS patients when compared to healthy controls. Our findings are corroborated by other studies showing that these miRNAs are upregulated in the circulation of OS patients [38, 39]. We further demonstrated that these three

![Figure 2](image_url)

**Figure 2**: Validation of the three miRNA candidates in the plasma samples of an independent cohort from the Children’s Oncology Group. Scatter plots to show higher miRNA expression levels of miR-21, miR-221 and miR-106a in the osteosarcoma (OS) plasma samples relative to the control samples of the validation set (A). Relative miRNA expression is expressed as normalized linear expression values ($2^{-\Delta Ct}$). Receiver Operating Characteristics analysis of the three miRNAs in discriminating the OS cases from the control cases (B). FC denotes fold change of OS/control samples.
miRNAs have high AUC values, suggesting they have good discriminatory power to distinguish OS patients from normal subjects, which could be used as non-invasive biomarkers for monitoring relapses and tumor burden in OS. Further investigations of longitudinal blood samples collected from different stages during the course of therapy, e.g. after definitive surgery and before and after relapses, are warranted to determine the clinical utility of these biomarkers for disease monitoring and early detection of relapses. In OS, a higher level of circulating miR-21 has been shown to correlate with initial metastasis, a poor tumor response to neoadjuvant chemotherapy and a reduced overall survival rate [40]. In addition, circulating miR-221 in OS has been shown to be a diagnostic biomarker and a prognostic biomarker for recurrence-free and overall survival [39]. Although our

Figure 3: Detection of the miR-21, miR-106a and miR-221 in osteosarcoma (OS) tissues. Scatter plots showing the tumor expression (-dCt) of miR-21, miR-106a and miR-221 in osteosarcoma tumor (n = 89) and normal bone (n = 5) samples as measured by qRT-PCR. (A) FC denotes fold change of OS/control samples. In-situ hybridization (ISH) 20× images showing the miR-21 expression (red) in OS tissues in formalin-fixed, paraffin embedded OS tissue microarray (B). The blue color indicates DAPI (4′,6-diamidino-2-phenylindole) stained nuclei. Left, middle and right panels show U6 (positive control), miR-21, and scrambled probe (negative control) images, respectively.
results confirmed that these two circulating miRNAs were elevated in OS plasma, no prognostic significance was found in our cohort. This discrepancy may be due to the relatively small sample size used in our discovery study, sample collection biases, and patient heterogeneity. A more extensive prognostic analysis of circulating miR-21 and miR-221 in a larger and adequately powered cohort will be needed to better determine their prognostic significance in OS.

In this study, we have reported an unbiased and genome-wide profiling of circulating miRNAs in OS patients and controls. These results allow us to compare our results with previous circulating miRNA biomarker findings in OS. Although most of the circulating

Figure 4: Kaplan-Meier analyses of miR-21 and miR-221 in the TARGET cases. miR-21 and miR-221 are significantly associated with overall (A) and event-free (B) survival when risk-stratified by 1st quartile of –dCt values. miR-21 and miR-221 are further independently prognostic from metastatic disease at diagnosis as well as significant in only the metastatic subpopulation for both overall (C) and event-free (D) survival. miR-21 alone also significantly stratifies patients presenting with no metastasis at diagnosis (D). All statistics presented were computed by log-rank tests.
miRNA studies in OS have involved specific preselected miRNAs, three studies have used miRNA profiling [41–43]. One miRNA profiling study identified a diagnostic biomarker panel of 4 upregulated miRNAs (miR-195-5p, miR-199a-3p, miR-320a, and miR-374a-5p), which are significantly reduced in postoperative samples [42]. Corroborated by our findings, they also found that miR-21, miR-199a-3p, miR-107, miR-335 and miR-374a-5p are upregulated in OS plasma. Another miRNA profiling study identified a higher level of circulating miR-199a-5p in OS patients, which is consistent with our profiling results [43]. However, they did not observe higher levels of circulating miR-21, miR-221 or miR-106a in OS patients. Finally, Li et al. found that circulating miR-106a is downregulated in OS, which is contradictory to our finding [41]. The discrepancies among these previous studies and our study may be due to different experimental designs, such as the use of pooled samples, U6 as a normalizer, and small sample sizes. The use of different biological samples, such as serum vs. plasma, and control samples may also contribute to the variations among these studies.

Figure 5: Correlation of miRNAs with known prognostic factors and among themselves. The differential expression of miR-106a (A) and miR-21 (B) with metastasis at diagnosis and histologic response. FC denotes fold change of ME/NM and GR/PR samples. ME, NM, GR and PR denote metastasis, no metastasis, good response and poor response, respectively. The expressions of miR-21 and miR-221 were highly positively correlated to one another in osteosarcoma samples (C) whereas miR-106a exhibits negative correlation with both miR-21 (D) and miR-221 (E). R represents the Pearson correlation coefficient. Comparing the risk-stratified grouping with respect to miR-21 and miR-221 shows that most patients fall into the same risk group, and are statistically significant using Fisher’s exact test (F).
In the preselected miRNA studies, circulating miR-21 and miR-221 were shown to be expressed higher in OS, which are consistent with our results [38–40]. Recently, miR-223 and miR-148a were identified as diagnostic and prognostic biomarkers and miR-34b was found to be associated with clinical risk in OS [44–46], but their results were not confirmed in our profiling data. In summary, both similarities and dissimilarities are found when we compare our study with the previous miRNA studies in OS. This may be due to the use of different normalization methods, patient cohorts, and miRNA quantitation methodologies in different studies. Standardization of the normalization method and increase of the sample size in future circulating miRNA studies will help to validate the diagnostic and prognostic significance of the biomarker candidates identified in these studies.

In addition to the circulating biomarkers, we also showed that miR-21 is upregulated in OS tumor tissues relative to bone controls, which is consistent with previous studies [47]. Since there are no widely accepted bone controls in the field, we used fetal and adult bone cells as well as normal osteoblasts as the controls in this study. Nonetheless, because of the small sample size ($n = 5$) and heterogeneous nature of the bone controls, the lack of differential expression of miR-221 and miR-106a in OS vs. controls needs to be interpreted with caution. More interestingly, we showed that lower expressions of miR-21 and miR-221 in OS tumors are associated with poor overall and event-free survival. Nonetheless, Ren et al. described that higher miR-21 expression predicts poor overall and disease-free survival in OS [48]. These contradictory findings may be explained by differences in race (multiracial in our study vs. single race in their study), age (97% of patient population less than 25 years old in our study compared to 63% in their study), miRNA quantification procedures, and treatment regimens in respective cohorts. To our knowledge, this is the first study to report the prognostic significance of tumor miR-221 in OS.

Furthermore, our correlation and multivariate survival analysis results further suggest that the tumor expressions of the two miRNAs, miR-21 and miR-221, are highly correlated, with miR-221 remaining the most significant prognostic biomarker after adjusting for the other two miRNAs in OS. Our analysis result also showed that miR-21 and miR-221 were not independent prognostic factors from the histologic response. miR-21 significantly correlated with histologic response, which can only be measured after the completion of adjuvant chemotherapy. Attempts to modify postoperative chemotherapy have not yielded any significant survival benefit, suggesting that an early predictive biomarker before the treatment initiation would be clinically preferable [49]. Upon further validation, miR-221 and miR-21 may be used as a novel prognostic and predictive biomarkers, respectively, at the time of diagnosis, so that alternative or more aggressive therapies could be offered up front, if available, to improve their survival.

miR-21 has been found to be upregulated across six major types of cancers [50] and considered to be an oncogene [29, 51]. It has been shown to promote cancer development and progression [52], inhibit tumor suppressor genes [53–55], and regulate chemosensitivity [56, 57]. As a biomarker in OS, circulating miR-21 has been shown to be upregulated in OS serum [40], plasma [38] and tumors [47, 48]. One of these studies further showed that a higher level of circulating miR-21 correlates with advanced Enneking stage, poor tumor response to neoadjuvant chemotherapy and a reduced overall survival rate in OS [40]. Functionally, miR-21 has been shown to promote metastatic potential through modulation of the tumor suppressor protein RECK expression in an OS cell line [47]. It can also enhance proliferation, invasion and inhibit apoptosis through PTEN/PI3K pathway in OS cells [58]. Inversely, p16 INK4A (a CDK inhibitor) decreases the migratory and invasive capabilities of OS cells through miR-21 downregulation [59]. Thus, it was puzzling why lower expression of tumor miR-21 correlated with a poor histologic response and a poor outcome in our study. However, most of these functional studies are in vitro studies with OS cell lines, the in vivo function of miR-21 in the tumor is still unclear. Nevertheless, lower miR-21 expression significantly correlates with poor survival in some cancers, including non-small lung carcinoma [60], diffuse large B cell lymphoma [61], and colorectal cancer [62], suggesting that miR-21 can also act as a positive prognostic factor. More importantly, OS is prone to chemoresistance and a recent study has revealed that lower miR-21 levels lead to increased cisplatin resistance in OS [63]. Hence, we postulate that lower expression of miR-21 may increase cisplatin resistance in OS, which leads to poor histologic response and survival of the patients. However, further validation of the prognostic significance of miR-21 in OS patients and in vivo analysis of its function in a mouse model of OS will be needed to shed light on the role of miR-21 in OS.

Similar to the previous studies in prostate cancer [64, 65] and breast cancer [66], our results showed that lower miR-21 expression in OS tumors correlated with poor prognosis. However, other studies showed that higher miR-21 expression correlates with poor prognosis in solid tumors, including colon cancer [20], non-small cell lung cancer [23], and glioma [67]. The miR-21 has important biological roles in regulating tumor progression, tumorigenesis, stem cell phenotype, chemoresistance, tumor cell proliferation and radioresistance [30, 68–71]. The known downstream targets of miR-221 include HDAC6 [68], DNMT3b [70], NOSTRIN [72], E-cadherin [73], uPAR7b [74], PTEN [75] and the tumor suppressor proteins p27 and p57 [76]. Interestingly, we have recently reported that p27 (KIP1 and CDKN1B), a known direct target of miR-221 [76], is frequently mislocalized to the cytoplasm of OS tumors, which increases tumor cell
migration and invasion and metastasis in OS [77]. Our working model is that low expression of miR-21 may lead to overexpression of p27, which is exported from the nucleus to the cytoplasm. The overexpression and mislocalization of p27 promote tumor progression and metastasis, thus leading to a poor outcome in OS patients. This finding led us to further postulate that replacement of miR-221 expression in high-risk OS cases may lead to downregulation of cytoplasmic p27 and decrease the metastatic potential of OS cells. To support this notion, we have previously demonstrated that silencing p27 expression in OS cells harboring cytoplasmic p27 can lead to lower motility and invasiveness [77]. miRNA replacement therapy is an emerging and promising field in cancer therapy, which has recently attracted a lot of interest. Clinical trials are currently underway to evaluate the safety and efficacy of miRNA therapeutics, such as the use of MRX34 encapsulated in a liposomal nanoparticle in cancer treatment [78]. A similar strategy could be explored to evaluate the therapeutic effect of miR-221 in OS.

miR-106a was one of the first miRNAs shown to be overexpressed in multiple solid tumor types by a large scale miRNAome analysis [50]. In OS, the role of miR-106a is still unclear. miR-106a has been found to be overexpressed in OS cell lines when compared to normal bones [27], and in OS tumors when compared to both human osteoblasts and mesenchymal stem cells [79], while lower miR-106a expression in OS has also been reported [80]. In this study, we did not find that miR-106a was significantly upregulated or downregulated in OS tumors when compared to the normal bone controls. The increase of miR-106a in the plasma of OS patients may be derived from other tissues in the body rather than the tumor itself.

Contrary to previous studies of circulating miRNAs in OS, we have reported genome-wide profiling of circulating miRNAs in OS patients and controls. Our study has also addressed some of the weaknesses in earlier OS studies with miRNA profiling, such as the use of pooled samples, questionable control (U6), and small sample size [41–43]. Despite the differences in methodology, upregulation of circulating miR-21, miR-221, and miR-106a in OS has been observed in previous studies [38–40, 42]. Nevertheless, this study had its own limitations. Due to the lack of matched tissue and plasma samples, the correlation between tumor and blood expression of the three miRNAs could not be properly evaluated. Hence, the question whether the circulating miRNAs are derived or released from tumor cells is still unclear. Another limitation is that longitudinal samples were not available to evaluate the utility of the circulating miRNAs in monitoring tumor burden and relapses.

In summary, our current study has identified and validated the elevated levels of circulating miR-21, miR-221, and miR-106a in OS, suggesting that they could be potentially used as non-invasive biomarkers for detecting OS, monitoring disease burden, and/or detecting early relapse. We have further demonstrated that miR-21 is upregulated in OS tumors and the expressions of miR-21 and miR-221 are prognostically significant in a large cohort of OS patients. Functional studies with miRNA mimics to further dissect the anti-tumor roles of miR-21 and miR-221 in OS may lead to the development of novel miRNA-based therapeutics to improve the survival of OS patients with a poor prognosis.

MATERIALS AND METHODS

Patient samples and characteristics

To conduct genome-wide miRNA profiling to discover biomarker candidates, plasma samples from 32 OS patients were used. The samples were collected at the time of diagnosis from the Texas Children’s Hospital (TCH) and other collaborating institutions. The patient characteristics are summarized in Supplementary Table 6 [81]. All patients gave consent to institutional review board-approved protocols. The patient samples were compared with normal plasma samples (n = 8). Four of the normal samples were obtained from Equitech Enterprises, Inc. (Kerrville, TX) and the rest from anonymized patients with noncancerous diseases (n = 4), i.e. child checkup, flu, constipation, gastroenteritis, or febrile seizure. To validate the three miRNA candidates, OS plasma samples (n = 29) were obtained from the Children’s Oncology Group (Protocol H-6650 and H-31361). The patient samples were compared with control plasma samples from 18 year-old healthy individuals (n = 17) from Bioreclamation LLC (Hicksville, NY). The patient characteristics of the validation cohort are summarized in Supplementary Table 6 [82].

Plasma sample processing

All the plasma samples were collected in EDTA-containing tubes and the plasma supernatant was collected after centrifugation in their respective standard protocols, e.g. 1,000 rpm for 10 min at RT for the TCH samples, and stored in aliquots at −80°C until use.

miRNA profiling in plasma

Total RNAs, including small RNAs (miRNA), were isolated from plasma samples (50 µL) using the miRNAeasy Mini Kit according to manufacturer’s protocol (Qiagen, Inc., Valencia, CA). Each reverse transcription (RT) reaction consisted of 72 µL RT master mix from miRCURY universal cDNA synthesis kit (Exiqon, Inc., Woburn, MA) and 8 µL of RNA to generate 80 µL cDNA. The cDNA of each plasma sample was then diluted to 4.4 mL with water and then combined with 4.4 mL of PCR SYBR green master mix (Exiqon) and miRNA expression
profiling was carried out using the miRCURY LNA™ Universal RT miRNA PCR, Ready-to-Use Human Panel I V2 (Exiqon). Two of these panels were run for each plasma sample. The PCR reactions were performed on a LightCycler 480 (Roche Diagnostics Corp, Indianapolis, IN) to generate the raw Cq value for each of the miRNA in the patient and control samples.

miRNA assays to validate miR-21, miR-221, and miR-106a

Each plasma sample (250 µL) was filtered using a 0.22 µm filter of which 200 µL was used for RNA extraction. Qiazol lysis reagent was used for sample denaturation. Carrier RNA from the bacteriophage MS2 (0.625 ng) was added to minimize the loss of small RNA molecules followed by chloroform (50 µL) for separation of miRNAs. miRNAeasy silica spin columns from Qiagen were used to isolate miRNAs as per manufacturer’s instructions and were eluted in a 50 µL volume of nuclease free water and stored at −80°C. miRCURY universal cDNA synthesis kit was used for first strand cDNA synthesis from 1 µL of RNA. RT reactions were done on a PTC-100 thermocycler (Bio-Rad Laboratories, Inc., Hercules, CA) and samples were stored at −20°C. The spike-in synthetic RNAs, UniSp2 and UniSp6 (Exiqon) were used to monitor the efficiency of the RNA extraction and cDNA synthesis, respectively. Four microliters of cDNA (diluted 1:20 in nuclease free water) were used in qPCR reactions done in duplicates in a final volume of 10 µL consisting of 5 µL of PCR SYBR green master mix and 1 µL of specific PCR primer (Exiqon) on ABI StepOnePlus real time PCR system (ThermoFisher Scientific, Waltham, MA). The method has been previously described in [82].

miRNA in situ hybridization (ISH)

miRCURY LNA miRNA ISH optimization kit was used for in situ hybridization of miRNA in formalin-fixed and paraffin-embedded OS tissue microarrays (TMA, Imgenex Corp, Littleton, CO). The clinical characteristics of the OS cases in the TMA are described in Supplementary Table 7. The TMA’s were first deparaffinized in xylene and rehydrated with an ethanol gradient. Proteinase K unmasking was done by treating with 20 µg/ml Proteinase K (Exiqon) for 10 min at 37°C. The TMA’s were fixed with 4% formaldehyde in PBS followed by EDC (1-Ethyl-3-(3-dimethylaminopropyl carbodiimide). miR-21, U6, and negative control (scrambled miRNA) probes with LNA-modified and 5'- and 3'-DIG-labeled oligonucleotides (Exiqon) were tested in each experiment. They were prepared in the hybridization buffer containing yeast tRNA, formamide, heparin, and 0.1 % Tween 20 and incubated with the tissue spots for 1 hour covered with HybriSlip (Electron Microscopy Sciences, Hatfield, PA). After a couple of washes in Saline Sodium Citrate buffer, the TMA’s were blocked in BSA/PBS for 30 minutes at RT followed by incubation with anti-Digoxigenin-POD Fab fragments (Roche Diagnostics) for 1 hour at RT. The slides were washed with PBST and followed by Cy5 tyramide detection (TSA-Plus cyanine 5 System, PerkinElmer, Inc, Waltham, MA). Slides were then mounted with Prolong gold antifade reagent with DAPI (ThermoFisher Scientific). The signals and images of the probes were detected and captured using Nikon Eclipse E800 with a 20× magnification.

Data analysis of plasma miRNAs

In the miRNA profiling analysis, raw miRNA Cq values were normalized by the sum of miR-320a and miR-15a-5p expression values to derive dCq values similar to previously described [82], and the negative dCq values were used as normalized miRNA expressions. miRNAs with missing values were filtered, resulting totally 313 miRNAs for the statistical analysis. Differential expression analysis was performed using 2-sample t-test with confidence level of 90% and false discoveries of 5% as implemented in BRB ArrayTools [83]. The significant miRNAs were used to construct the heatmap with hierarchical clustering of Euclidean distance and average linkage using Multi-Experiment Viewer (MeV) [84]. The expression values (Cq) were mean-normalized by row. The ROC graphs were generated by Prism (GraphPad software, Inc, La Jolla, CA). For the validation analysis, a sum of miR-320a, miR-15a-5p and UniSp2 were used for normalization [82]. Differential expression was performed using a two-sample, two-tailed t-test comparing the 2 –dCq values of the two groups (p < 0.05).

Data analysis of tumor miRNAs

To determine whether the tumor expression of the three miRNAs identified in blood analysis were also differentially expressed and prognostically significant in tumor samples, we analyzed the miRNA data generated from 89 OS tumors from the NCI’s TARGET consortium. The data are available for download at https://ocg.cancer.gov/programs/target/using-target-data. The normal controls consisted of two fetal bone samples and two adult bone samples, and the normal human osteoblasts (NHOst) were purchased from the BioChain Institute (Newark, CA). The flow-through from the Qiagen DNA column was processed as normalized miRNA expressions. miRNAs with missing values were filtered, resulting totally 313 miRNAs for the statistical analysis. The data are available for download at https://ocg.cancer.gov/programs/target/using-target-data. The normal controls consisted of two fetal bone samples and two adult bone samples, and the normal human osteoblasts (NHOst) were purchased from the BioChain Institute (Newark, CA). The TaqMan Low Density Array (TLDA) Human MicroRNA Panel (Applied Biosystems, Inc., Foster City, CA) platform was employed for miRNA profiling. All experimental procedures and conditions were conducted according to manufacturer’s protocols. ΔCt values for
each miRNA were computed relative to U6 for each card. Missing values were imputed using the imputation package (k = 10). The negative ΔCt values of miR-21, miR-221, and miR-106a were used for the statistical analyses. Detailed description of the data and pre-processing methods is published elsewhere. Correlation with clinical covariates, such as metastasis status at diagnosis and histologic response, was analyzed using 2-sample, unpaired t-tests. Expression was further analyzed with respect to overall and event-free survival using continuous Cox Proportional Hazards models (COXPH). Kaplan-Meier curves were generated using first quartile expression value for each miRNA as a cutoff. Stratified analyses were performed with the miRNA expression and clinical covariates. Significance was determined using the two-tailed log-rank statistic for all survival analyses. 5-year survival estimates for all Kaplan-Meier curves are provided with 95% confidence intervals. p < 0.05 was considered significant in all statistical tests. Metastasis at diagnosis refers to whether a patient had presence of any detectable metastatic lesions at the time of diagnosis, whereas histologic response refers to greater than (“good” response) or less than (“poor” response) 90% tumor cell necrosis from preoperative chemotherapy observed after definitive surgery. HR refers to “hazard ratio”.

ACKNOWLEDGMENTS

We are very thankful to the Bone Sarcoma Committee with COG for their support in providing the validation samples used in this study. We are also grateful to Dr. Gregory L. Shipley for his help and advice in the plasma miRNA profiling. We thank the members of the NCI’s TARGET consortium for the permission to use the tumor miRNA data. We also thank Drs. Lisa Wang, Laszlo Perlaky, Murali Chintagumpala, Jeffery Murray and William Myers for their assistance in collecting the plasma samples as well as Carolyn Pena for proofreading the manuscript.

CONFLICTS OF INTEREST

The authors disclosed no potential conflicts of interest.

FUNDING

This work was partly supported by R01 HD074553 from the National Institute of Child Health and Human Development (TKM), and RP101335-P2/RP140022-P2 (TKM and CL) and RP140102 (AK) from the Cancer Prevention and Research Institute of Texas. Additional support was received by a grant from the QuadW Foundation, Inc. (www.QuadW.org) to the Children’s Oncology Group. This work was supported in part by grants from the Ontario Research Fund, and the Canadian Foundation for Innovation (ILA and JSW).

REFERENCES

1. Dorfman HD, Czerniak B. Bone cancers. Cancer. 1995; 75:203–10.
2. Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer. 2009; 115:1531–43.
3. Link MP, Goorin AM, Miser AW, Green AA, Pratt CB, Belasco JB, Pritchard J, Malpas JS, Baker AR, Kirkpatrick JA, Ayala AG, Shuster JJ, Abelson HT, et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med. 1986; 314:1600–6.
4. Szendroi M, Papai Z, Koos R, Illes T. Limb-saving surgery, survival, and prognostic factors for osteosarcoma: the Hungarian experience. J Surg Oncol. 2000; 73:87–94.
5. Zhao JJ, Lin J, Yang H, Kong W, He L, Ma X, Coppola D, Cheng JQ. MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. J Biol Chem. 2008; 283:31079–86.
6. Tsuchiya H, Kanazawa Y, Abdel-Wanis ME, Asada N, Abe S, Isu K, Sugita T, Tomita K. Effect of timing of pulmonary metastases identification on prognosis of patients with osteosarcoma: the Japanese Musculoskeletal Oncology Group study. J Clin Oncol. 2002; 20:3470–7.
7. Lyng MB, Kodahl AR, Binder H, Ditzel HJ. Prospective validation of a blood-based 9-miRNA profile for early detection of breast cancer in a cohort of women examined by clinical mammography. Mol Oncol. 2016; 10:1621–6.
8. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009; 136:215–33.
9. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O’Briant KC, Allen A, Lin DW, Urban N, Drescher CW, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008; 105:10513–8.
10. Cortez MA, Bueso-Ramos C, Ferdin J, Lopez-Berestein G, Sood AK, Calin GA. MicroRNAs in body fluids—the mix of hormones and biomarkers. Nat Rev Clin Oncol. 2011; 8:467–77.
11. Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, Banham AH, Pezzella F, Boulwood J, Wainscoat JS, Hatton CS, Harris AL. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol. 2008; 141:672–5.
12. Toiyama Y, Takahashi M, Hur K, Nagasaka T, Tanaka K, Inoue Y, Kusunoki M, Boland CR, Goel A. Serum miR-21 as a diagnostic and prognostic biomarker in colorectal cancer. J Natl Cancer Inst. 2013; 105:849–59.
13. Li J, Liu Y, Wang C, Deng T, Liang H, Wang Y, Huang D, Fan Q, Wang X, Ning T, Liu R, Zhang CY, Zen K, et al. Serum miRNA expression profile as a prognostic biomarker
of stage II/III colorectal adenocarcinoma. Sci Rep. 2015; 5:12921.

14. Chen W, Cai F, Zhang B, Barekati Z, Zhong XY. The level of circulating miRNA-10b and miRNA-373 in detecting lymph node metastasis of breast cancer: potential biomarkers. Tumour Biol. 2013; 34:455–62.

15. Imaoka H, Toiyama Y, Okigami M, Yasuda H, Saigusa S, Ohi M, Tanaka K, Inoue Y, Mohri Y, Kusunoki M. Circulating microRNA-203 predicts metastases, early recurrence, and poor prognosis in human gastric cancer. Gastric Cancer. 2016; 19:744–53.

16. Zhu C, Ren C, Han J, Ding Y, Du J, Dai N, Dai J, Ma H, Hu Z, Shen H, Xu Y, Jin G. A five-microRNA panel in plasma was identified as potential biomarker for early detection of gastric cancer. Br J Cancer. 2014; 110:2291–9.

17. Jia W, Wu Y, Zhang Q, Gao GE, Zhang C, Xiang Y. Expression profile of circulating microRNAs as a promising fingerprint for cervical cancer diagnosis and monitoring. Mol Clin Oncol. 2015; 3:851–8.

18. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006; 6:857–66.

19. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, Stephens RM, Omakoto A, Yokota J, Tanaka T, Calin GA, Liu CG, Croce CM, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell. 2006; 9:189–98.

20. Cai K, Shen F, Cui JH, Yu Y, Pan HQ. Expression of miR-221 in colon cancer correlates with prognosis. Int J Clin Exp Med. 2015; 8:2794–8.

21. Kristensen H, Thomsen AR, Haldrup C, Dyrsjot L, Hoyer S, Borre M, Mouritzen P, Ormtøft TF, Sorensen KD. Novel diagnostic and prognostic classifiers for prostate cancer identified by genome-wide microRNA profiling. Oncotarget. 2016; 7:30760–71. https://doi.org/10.18632/oncotarget.8953.

22. Xue L, Wang Y, Yue S, Zhang J. The expression of miRNA-221 and miRNA-222 in gliomas patients and their prognosis. Neur Sci. 2017; 38:67–73.

23. Zhang Y, Zhao Y, Sun S, Liu Z, Zhang Y, Jiao S. Overexpression of MicroRNA-221 is associated with poor prognosis in non-small cell lung cancer patients. Tumour Biol. 2016; 37:10155–60.

24. Renwick N, Cekan P, Masry PA, McGeary SE, Miller JB, Hafner M, Li Z, Mihailovic A, Morozov P, Brown M, Gogakos T, Mobin MB, Snorrason EL, et al. Multicolor microRNA FISH effectively differentiates tumor types. J Clin Invest. 2013; 123:2694–702.

25. Hanniford D, Zhong J, Koetz L, Gaziel-Sovran A, Lackaye DJ, Shang S, Pavlick A, Shapiro R, Berman R, Darvishian F, Shao Y, Osman I, Hernando E. A miRNA-Based Signature Detected in Primary Melanoma Tissue Predicts Development of Brain Metastasis. Clin Cancer Res. 2015; 21:4903–12.

26. Saito M, Shiraishi K, Matsumoto K, Schetter AJ, Ogata-Kawata H, Tsuchiya N, Kunitoh H, Nokihara H, Watanabe S, Tsuta K, Kumamoto K, Takenoshita S, Yokota J, et al. A three-microRNA signature predicts responses to platinum-based doublet chemotherapy in patients with lung adenocarcinoma. Clin Cancer Res. 2014; 20:4784–93.

27. Namlos HM, Meza-Zepeda LA, Barot T, Ostensen IH, Kresse SH, Kuijjer ML, Serra M, Burger H, Clifton-Jansen AM, Myklebost O. Modulation of the osteosarcoma expression phenotype by microRNAs. PLoS One. 2012; 7:e48086.

28. Dylla L, Jedlicka P. Growth-promoting role of the miR-106a–363 cluster in Ewing sarcoma. PLoS One. 2013; 8:e63032.

29. Medina PP, Norde M, Slack FJ. OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. Nature. 2010; 467:86–90.

30. Pineau P, Volinia S, McJunik K, Marchio A, Battiston C, Terris B, Mazzafarro V, Lowe SW, Croce CM, Dejean A. miR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci U S A. 2010; 107:264–9.

31. Kawaguchi T, Komatsu S, Ichikawa D, Morimura R, Tsujiura M, Konishi H, Takeshita H, Nagata H, Arita T, Hirajima S, Shiozaki A, Ikoma H, Okamoto K, et al. Clinical impact of circulating miR-221 in plasma of patients with pancreatic cancer. Br J Cancer. 2013; 108:361–9.

32. Tsujiura M, Ichikawa D, Komatsu S, Shiozaki A, Takeshita H, Kosuga T, Konishi H, Morimura R, Deguchi K, Fujihara H, Okamoto K, Otsuji E. Circulating microRNAs in plasma of patients with gastric cancers. Br J Cancer. 2010; 102:1174–9.

33. Schwarzenbach H, Nishida N, Calin GA, Pantel K. Clinical relevance of circulating cell-free microRNAs in cancer. Nat Rev Clin Oncol. 2014; 11:45–56.

34. Weber JA, Baxter DH, Zhang S, Huang DY, Huang KH, Lee MJ, Galas DJ, Wang K. The microRNA spectrum in 12 body fluids. Clin Chem. 2010; 56:1733–41.

35. Schrauder MG, Strick R, Schulz-Wendtland R, Strissel PL, Kahnmann L, Loebberg CR, Lux MP, Jud SM, Hartmann A, Hein A, Bayer CM, Bani MR, Richter S, et al. Circulating micro-RNAs as potential blood-based markers for early stage breast cancer detection. PLoS One. 2012; 7:e29770.

36. Wång K, Yuan Y, Cho JH, McClarty S, Baxter D, Galas DJ. Comparing the MicroRNA spectrum between serum and plasma. PLoS One. 2012; 7:e41561.

37. O’Brien KP, Ramphul E, Howard L, Gallagher WM, Malone C, Kerin MJ, Dwyer RM. Circulating MicroRNAs in Cancer. Methods Mol Biol. 2017; 1509:123–39.

38. Ouyang L, Liu P, Yang S, Ye S, Xu W, Liu X. A three-microRNA signature serves as novel biomarkers for osteosarcoma. Med Oncol. 2013; 30:340.

39. Yang Z, Zhang Y, Zhang X, Zhang M, Liu H, Zhang S, Qi B, Sun X. Serum microRNA-221 functions as a potential diagnostic and prognostic marker for patients with osteosarcoma. Biomed Pharmacother. 2015; 75:153–8.
50. V olinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Viale G, Mancini M, Donati P, et al. MicroRNA expression signature in human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A. 2004; 101:9947–52.

51. Lawrie CH, Soneji S, Marafioti T, Paterson JC, Sung J, Calvo V, Paterson AD, Hainaut P, et al. MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma. Cancer Res. 2010; 70:8288–98.

52. Voortman J, Goti A, Mendiboure J, Schetter AJ, Paterson AD, Sung J, Calvo V, Hainaut P, et al. MicroRNA expression signature in human solid tumors identifies cancer gene targets. Proc Natl Acad Sci U S A. 2006; 104:1948–53.

53. Dandoloff M, Cicala C, Calin GA, Haisma HJ, Rusch V, Azzarelli B, Bonadonna R, et al. MicroRNA expression in human cancer: correlation with clinical outcome. Cancer Res. 2006; 66:7812–16.

54. Darido C, Georgy S, Wilanowski T, Dworkin S, Auden A, Zhao Q, Rank G, Srivastava S, Finlay MJ, Papenfuss AT, Pandolfi PP, Pearson RB, Jane SM. Targeting of the tumor suppressor GRHL3 by a miR-21-dependent proto-oncogenic network results in PTEN loss and tumorigenesis. Cancer Cell. 2011; 20:635–48.

55. Zhu S, Si ML, Wu H, Mo YY. MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). J Biol Chem. 2007; 282:14328–36.

56. De Mattos-Arruda L, Bottai G, Nuti PG, Di Toma M, Santin D, Cimino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Paterson AD, Sung J, Calvo V, Hainaut P, et al. MicroRNA expression correlates with clinical outcome in patients with colorectal cancer. Cancer Res. 2008; 68:3097–104.

57. van de Vijver MJ, He YD, van’t Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002; 347:1999–2009.

58. van de Vijver MJ, He YD, van’t Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002; 347:1999–2009.

59. van de Vijver MJ, He YD, van’t Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002; 347:1999–2009.

60. van de Vijver MJ, He YD, van’t Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002; 347:1999–2009.

61. van de Vijver MJ, He YD, van’t Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002; 347:1999–2009.

62. van de Vijver MJ, He YD, van’t Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002; 347:1999–2009.

63. van de Vijver MJ, He YD, van’t Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002; 347:1999–2009.

64. van de Vijver MJ, He YD, van’t Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002; 347:1999–2009.

65. van de Vijver MJ, He YD, van’t Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002; 347:1999–2009.
65. Kneitz B, Krebs M, Kalogirou C, Schubert M, Joniau S, van Poppel H, Lerut E, Kneitz S, Scholz CJ, Strobel P, Gessler M, Riedmüller H, Spahn M. Survival in patients with high-risk prostate cancer is predicted by miR-221, which regulates proliferation, apoptosis, and invasion of prostate cancer cells by inhibiting IRF2 and SOCS3. Cancer Res. 2014; 74:2591–603.

66. Hanna JA, Wimberly H, Kumar S, Slack F, Agarwal S, Rimm DL. Quantitative analysis of microRNAs in tissue microarrays by in situ hybridization. Biotechniques. 2012; 52:235–45.

67. Li X, Zheng J, Chen L, Diao H, Liu Y. Predictive and Prognostic Roles of Abnormal Expression of Tissue miR-125b, miR-221, and miR-222 in Glioma. Mol Neurobiol. 2016; 53:577–83.

68. Bae HJ, Jung KH, Eun JW, Shen Q, Kim HS, Park SJ, Shin WC, Yang HD, Park WS, Lee JY, Nam SW. MicroRNA-221 governs tumor suppressor HDAC6 to potentiate malignant progression of liver cancer. J Hepatol. 2015; 63:408–19.

69. Chun-Zhi Z, Lei H, An-Ling Z, Yan-Chao F, Xiao Y, Guang-Xiu W, Zhi-Fan J, Pei-Yu P, Qing-Yu Z, Chun-Sheng K. MicroRNA-221 and microRNA-222 regulate gastric carcinoma cell proliferation and radioresistance by targeting PTEN. BMC Cancer. 2010; 10:367.

70. Roscigno G, Quintavalle C, Donnarumma E, Puoti I, Diaz-Lagares A, Iaboni M, Fiore D, Russo V, Todaro M, Romano G, Thomas R, Cortino G, Gaggiamesi M, et al. MiR-221 promotes stemness of breast cancer cells by targeting DNMT3b. Oncotarget. 2016; 7:580–92. https://doi.org/10.18632/oncotarget.5979.

71. Wei Y, Lai X, Yu S, Chen S, Ma Y, Zhang Y, Li H, Zhuo X, Yao L, Zhang J. Exosomal miR-221/222 enhances tamoxifen resistance in recipient ER-positive breast cancer cells. Breast Cancer Res Treat. 2014; 147:423–31.

72. Wang J, Yang S, He P, Schetter A, Gaedeke J, Ghadimi BM, Ried T, Yfantis HG, Lee DH, Gaida MM, Hanna N, Alexander HR, Hussain SP. Endothelial Nitric Oxide Synthase Traffic Inducer (NOSTRIN) is a Negative Regulator of Disease Aggressiveness in Pancreatic Cancer. Clin Cancer Res. 2016; 22:5992–6001.

73. Pan Y, Li J, Zhang Y, Wang N, Liang H, Liu Y, Zhang CY, Zen K, Gu H. Slug-upregulated miR-221 promotes breast cancer progression through suppressing E-cadherin expression. Sci Rep. 2016; 6:25798.

74. Falkenberg N, Anastasov N, Schauba A, Radulovic V, Schmitt M, Magdolen V, Aubele M. Secreted uPAR isoform 2 (uPAR7b) is a novel direct target of miR-221. Oncotarget. 2015; 6:8103–14. https://doi.org/10.18632/oncotarget.3516.

75. Lu J, Wang L, Li C, Yang H, Li Y, Hu H, Li H, Zhang Z. MicroRNA-221 targets PTEN to reduce the sensitivity of cervical cancer cells to gefitinib through the PI3K/Akt signaling pathway. Tumour Biol. 2016; 37:3939–47.

76. Kim YK, Yu J, Han TS, Park SY, Namkoong B, Kim DH, Hur K, Yoo MW, Lee HJ, Yang HK, Kim VN. Functional links between clustered microRNAs: suppression of cell-cycle inhibitors by microRNA clusters in gastric cancer. Nucleic Acids Res. 2009; 37:1672–81.

77. Li Y, Nakka M, Kelly AJ, Lau CC, Krailo M, Barkauskas DA, Hicks JM, Man TK. p27 Is a Candidate Prognostic Biomarker and Metastatic Promoter in Osteosarcoma. Cancer Res. 2016; 76:4002–11.

78. Ling H, Fabbri M, Calin GA. MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov. 2013; 12:847–65.

79. Arabi L, Gispone JR, Smida J, Nathrath M, Perrina V, Jundt G, Ruiz C, Quaglia L, Baumhoer D. Upregulation of the miR-17-92 cluster and its two paralogas in osteosarcoma - reasons and consequences. Genes Cancer. 2014; 5:56–63. https://doi.org/10.18632 genesandcancer.6.

80. He QY, Wang GC, Zhang H, Tong DK, Ding C, Liu K, Ji F, Zhu X, Yang S. miR-106a-5p Suppresses the Proliferation, Migration, and Invasion of Osteosarcoma Cells by Targeting HMG2. DNA Cell Biol. 2016; 35:506–20.

81. Li Y, Dang TA, Shen J, Perlaky L, Hicks J, Murray J, Meyer W, Chintagumpala M, Lau CC, Man TK. Identification of a plasma proteomic signature to distinguish pediatric osteosarcoma from benign osteochondroma. Proteomics. 2006; 6:3426–35.

82. Allen-Rhoades W, Kurenbekova L, Satterfield L, Parikh N, Fuji D, Shuck RL, Rainusso N, Trucco M, Barkauskas DA, Jo E, Ahern C, Hilsenbeck S, Donehower LA, et al. Cross-species identification of a plasma microRNA signature for detection, therapeutic monitoring, and prognosis in osteosarcoma. Cancer Med. 2015; 4:977–88.

83. Simon R, Lam A, Li MC, Ngan M, Menenzes S, Zhao Y. Analysis of gene expression data using BRB-ArrayTools. Cancer Inform. 2007; 3:11–7.

84. Saeed AI, Sharov V, White J, Li J, Ngan M, Menenzes S, Zhao Y. Analysis of gene expression data using BRB-ArrayTools. Cancer Inform. 2007; 3:11–7.